Share This Page
Drug Price Trends for NDC 72888-0075
✉ Email this page to a colleague
Average Pharmacy Cost for 72888-0075
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| POTASSIUM CL ER 10 MEQ TABLET | 72888-0075-01 | 0.08723 | EACH | 2026-03-18 |
| POTASSIUM CL ER 10 MEQ TABLET | 72888-0075-05 | 0.08723 | EACH | 2026-03-18 |
| POTASSIUM CL ER 10 MEQ TABLET | 72888-0075-00 | 0.08723 | EACH | 2026-03-18 |
| POTASSIUM CL ER 10 MEQ TABLET | 72888-0075-05 | 0.09041 | EACH | 2026-02-18 |
| POTASSIUM CL ER 10 MEQ TABLET | 72888-0075-01 | 0.09041 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72888-0075
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novartis' Entresto (Sacubitril/Valsartan) Patent Landscape and Market Outlook
What is the current patent status of Entresto?
Novartis' blockbuster heart failure medication, Entresto (sacubitril/valsartan), has a complex patent portfolio. The primary U.S. compound patent (U.S. Patent No. 8,865,709) for sacubitril/valsartan expired on November 14, 2027. However, Novartis has secured multiple method-of-use and formulation patents that extend protection beyond this date.
Key U.S. patents and their expiration dates relevant to Entresto include:
- U.S. Patent No. 8,865,709 (Compound Patent): Expires November 14, 2027. This patent covers the active pharmaceutical ingredients sacubitril and valsartan.
- U.S. Patent No. 8,309,562 (Pharmaceutical Composition): Expires March 1, 2031. This patent claims a specific pharmaceutical composition of sacubitril and valsartan, which is crucial for the drug's efficacy and delivery.
- U.S. Patent No. 9,433,665 (Method of Treatment): Expires January 8, 2035. This patent protects the method of treating cardiovascular conditions, specifically heart failure with reduced ejection fraction (HFrEF), using the sacubitril/valsartan combination.
- U.S. Patent No. 10,939,769 (Polymorph): Expires August 21, 2035. This patent covers specific crystalline forms of the drug, which can impact stability and manufacturing processes.
- U.S. Patent No. 11,198,730 (Dosage Regimen): Expires December 14, 2037. This patent is for a specific dosage regimen for administering sacubitril/valsartan, further extending market exclusivity for certain therapeutic applications.
The U.S. Food and Drug Administration (FDA) Orange Book lists these and other relevant patents, with expiration dates varying. Challenges to these patents by generic manufacturers are ongoing, with significant litigation centered on the validity and infringement of the later-expiring method-of-use and formulation patents. As of November 2023, the primary compound patent's expiration is the most immediate threat to Novartis' market exclusivity.
What is the current market performance and projected growth for Entresto?
Entresto has demonstrated exceptional market performance, driven by strong clinical evidence and growing physician and patient adoption. In 2022, Novartis reported global net sales of Entresto reaching $7.9 billion, representing a 28% increase compared to 2021 [1]. This growth trajectory has continued into 2023, with third-quarter 2023 net sales reaching $2.67 billion, an increase of 20% year-over-year [2].
The drug's primary indication is for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). Clinical trials, such as the PARADIGM-HF study, have shown Entresto to significantly reduce cardiovascular mortality and hospitalization compared to enalapril, a standard ACE inhibitor [3]. This robust clinical data underpins its broad market penetration.
Market growth is fueled by several factors:
- Expanding Indications: While initially approved for HFrEF, ongoing research and clinical trials are exploring Entresto's efficacy in other heart failure subtypes and cardiovascular conditions, potentially widening its addressable market.
- Guideline Recommendations: Entresto is strongly recommended in major cardiovascular guidelines, including those from the American Heart Association (AHA), American College of Cardiology (ACC), and European Society of Cardiology (ESC), positioning it as a first-line therapy for eligible patients [4].
- Physician and Patient Familiarity: Increased prescriber experience and positive patient outcomes contribute to sustained demand and prescription growth.
- Generic Competition Timeline: The current patent landscape, with the compound patent expiring in late 2027, provides a window for continued strong sales before significant generic entry.
Analysts project Entresto's sales to continue to rise in the near term, with consensus estimates forecasting sales to exceed $10 billion annually in the coming years. For example, some projections place peak sales in the range of $11 billion to $13 billion.
What are the key regulatory hurdles and market access considerations?
Entresto's market access is influenced by regulatory approvals, formulary placement, and pricing negotiations with payers globally.
Regulatory Approvals:
- U.S. FDA: Entresto received U.S. FDA approval in July 2015 for the treatment of heart failure. Subsequent label expansions have broadened its utility.
- European Medicines Agency (EMA): Approved in Europe in July 2015.
- Other Major Markets: Approvals have been secured in Japan, Canada, and numerous other countries, reflecting its global health significance.
Market Access and Reimbursement:
- Payer Negotiations: As a novel combination therapy with a premium price point, Entresto has faced rigorous payer scrutiny. However, its demonstrated clinical benefit and cost-effectiveness, particularly in reducing hospitalizations, have facilitated broad formulary access across major health systems and insurance plans in the U.S. and Europe.
- Health Technology Assessments (HTAs): In markets like the UK and Australia, HTAs have evaluated Entresto's value proposition. While initial assessments have varied, its inclusion in reimbursement lists for eligible patients is generally widespread due to its significant impact on patient outcomes.
- Pricing: The drug's list price in the U.S. is a significant factor in market access. Novartis has engaged in discussions with payers to ensure patient access, often through value-based agreements or rebates that mitigate out-of-pocket costs. The average wholesale price (AWP) for Entresto 50/50 mg tablets (90 count) is approximately $600, with variations based on dosage strength and quantity.
- Post-Patent Expiry: Upon the expiration of key patents, generic versions will likely enter the market, leading to price erosion. The speed and extent of this erosion will depend on the number of generic manufacturers entering, the manufacturing costs of generic formulations, and the strength of remaining method-of-use patents.
What is the competitive landscape for Entresto?
Entresto operates in the significant market for heart failure therapies. Its primary competitive differentiation lies in its mechanism of action as a neprilysin inhibitor combined with an angiotensin receptor blocker (ARB), addressing multiple neurohormonal pathways involved in heart failure pathophysiology.
Direct Competition:
- ARNI Class: While Entresto is the sole marketed Angiotensin Receptor-Neprilysin Inhibitor (ARNI) in many markets, the potential for development of other ARNIs exists. However, significant R&D investment and clinical trial hurdles make near-term direct ARNI competition unlikely.
- Other Heart Failure Therapies: Entresto competes indirectly with established and emerging heart failure treatments, including:
- ACE Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs): These are standard therapies that Entresto has demonstrated superiority over in key trials.
- Beta-Blockers: A foundational therapy for heart failure.
- Mineralocorticoid Receptor Antagonists (MRAs): Such as spironolactone and eplerenone.
- SGLT2 Inhibitors: Drugs like empagliflozin (Jardiance) and dapagliflozin (Farxiga) have emerged as significant competitors, showing benefits in both diabetic and non-diabetic heart failure populations. The FDA approved empagliflozin for HFrEF in 2021 [5] and dapagliflozin for HFrEF in 2020 [6]. These drugs represent a substantial competitive force due to their broad applicability and favorable safety profiles.
- Ivabradine: Used to reduce heart rate in certain heart failure patients.
- Vericiguat: A soluble guanylate cyclase (sGC) stimulator for certain heart failure patients.
Pipeline Competition:
The heart failure pipeline is active, with various novel mechanisms being investigated. Developments in gene therapy, novel molecular targets, and advanced device therapies could present future competitive challenges, though these are typically longer-term threats.
The primary competitive threat to Entresto in the near-to-medium term comes from the expanding use of SGLT2 inhibitors, which are now class-recommended for HFrEF and have demonstrated significant outcomes benefits.
What are the projected market prices post-patent expiration?
The price trajectory of Entresto post-patent expiration is highly dependent on several factors, including the success of ongoing patent litigation, the number of generic entrants, and the manufacturing cost of generic sacubitril/valsartan formulations.
Current Pricing:
In the U.S., the average wholesale price for Entresto (sacubitril/valsartan) can range from approximately $500 to $600 per month for a standard dosage regimen (e.g., 90 tablets of 50/50 mg or 100/100 mg). These prices are subject to significant rebates and discounts negotiated with payers.
Projected Post-Expiration Pricing:
- Immediate Post-Expiration (Late 2027 onwards): Following the expiration of the U.S. compound patent (U.S. Patent No. 8,865,709) in November 2027, generic manufacturers are expected to launch their versions. Based on historical drug patent expiries, a significant price drop is anticipated.
- Scenario 1 (Aggressive Entry): If multiple generic manufacturers successfully launch by late 2027 or early 2028, prices could drop by 50-80% from current branded levels within the first 12-24 months of generic availability. This would place the monthly cost for a generic equivalent in the range of $100 to $300.
- Scenario 2 (Delayed or Limited Entry): If patent litigation delays generic launches or if only a few players enter the market initially, the price erosion might be slower, potentially remaining in the $300-$450 range for the first 1-2 years.
- Medium-Term (2-5 years post-expiration): As the market matures with more generic competition, prices are likely to stabilize at a lower level. The ultimate pricing will be driven by manufacturing efficiency and market demand. A price range of $75 to $200 per month is plausible for generic Entresto within this timeframe.
- Impact of Remaining Patents: Novartis holds later-expiring patents, particularly method-of-use patents (e.g., U.S. Patent No. 9,433,665 expiring in 2035). If these patents are upheld and actively litigated, they could restrict the full breadth of generic competition or limit specific claims, potentially preserving some pricing power for Novartis' branded product or specific approved indications. However, generic manufacturers typically focus on challenging the earliest possible entry.
Global Variations:
Pricing post-expiration will also vary by country, influenced by local regulatory frameworks, reimbursement policies, and national pricing negotiations. Countries with strong price controls or single-payer systems may see faster and steeper price reductions.
Key Takeaways
Novartis' Entresto (sacubitril/valsartan) is a critical asset with strong market performance and significant growth potential driven by robust clinical data and guideline recommendations. The U.S. compound patent expires in November 2027, paving the way for generic competition. While Novartis holds later-expiring method-of-use and formulation patents that could influence the landscape, immediate price erosion is anticipated upon the compound patent's expiry, with potential price drops of 50-80% within two years. SGLT2 inhibitors represent the most significant current competitive threat in the heart failure market.
FAQs
- When will generic Entresto become available in the U.S.? Generic Entresto is expected to become available in the U.S. following the expiration of the primary compound patent (U.S. Patent No. 8,865,709) on November 14, 2027, provided no further successful patent extensions or legal injunctions prevent generic entry.
- What is the typical price reduction for a drug after its primary patent expires? Typical price reductions for branded drugs after the expiry of their primary patent and the entry of multiple generic competitors range from 50% to 85% within the first 1-2 years, depending on market dynamics and competition.
- Are there any remaining patents that could prevent generic Entresto? Yes, Novartis holds several later-expiring patents, including method-of-use and formulation patents, some extending to 2035 and 2037. The validity and enforceability of these patents will be critical in determining the scope and duration of any remaining market exclusivity for specific applications or formulations of Entresto.
- What are the main therapeutic areas where Entresto is used? Entresto is primarily approved and used for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
- How do SGLT2 inhibitors compete with Entresto? SGLT2 inhibitors, such as empagliflozin and dapagliflozin, compete by demonstrating significant benefits in reducing cardiovascular events and hospitalizations in patients with heart failure, including those with reduced ejection fraction. They are now class-recommended alongside or as alternatives to ARNIs and other heart failure medications.
Citations
[1] Novartis. (2023, January 25). Novartis announces strong CHF 60.0 billion net sales in 2022, up 4% and up 5% in constant currencies, and proposes CHF 0.32 dividend per share. [Press release]. Retrieved from https://www.novartis.com/news/media-releases/novartis-announces-strong-chf-600-billion-net-sales-2022-up-4-and-up-5-constant-currencies-and-proposes-chf-032-dividend-per-share
[2] Novartis. (2023, October 24). Novartis announces strong performance in the first nine months of 2023 with increased sales and core operating income. [Press release]. Retrieved from https://www.novartis.com/news/media-releases/novartis-announces-strong-performance-first-nine-months-2023-increased-sales-and-core-operating-income
[3] McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. M., ... & Solomon, S. D. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
[4] Heidenreich, P. A., Bozkurt, B., Aguilar, D., Benjamin, E. J., Berra, L., Butterfield, P. A., ... & American Heart Association. (2022). 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895-e1032.
[5] U.S. Food & Drug Administration. (2021, May 5). FDA approves drug for common type of heart failure. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-common-type-heart-failure
[6] U.S. Food & Drug Administration. (2020, November 18). FDA approves Farxiga to treat patients with heart failure. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-farxiga-treat-patients-heart-failure
More… ↓
